# Shu Ye

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 142 papers | 10,200 citations | 50 h-index | 99 g-index |
| 149 ext. papers | 11,405 ext. citations | 7.1 avg, IF | 5.79 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 142 | Elucidating mechanisms of genetic cross-disease associations at the PROCR vascular disease locus.. *Nature Communications*, **2022**, 13, 1222 | 17.4 | 0 |
| 141 | BoxCar increases the depth and reproducibility of diabetic urinary proteome analysis. *Proteomics - Clinical Applications*, **2021**, 15, e2000092 | 3.1 | 0 |
| 140 | The Long Noncoding RNA RP11-728F11.4 Promotes Atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 1191-1204 | 9.4 | 3 |
| 139 | Expression in Vascular Endothelial Cells Is Modulated by a Coronary Artery Disease-Associated Genetic Variant and Influences Monocyte Transendothelial Migration. *Journal of the American Heart Association*, **2020**, 9, e014333 | 6 | 15 |
| 138 | Effect of a coronary-heart-disease-associated variant of ADAMTS7 on endothelial cell angiogenesis. *Atherosclerosis*, **2020**, 296, 11-17 | 3.1 | 1 |
| 137 | Genetic Associations With Plasma Angiotensin Converting Enzyme 2 Concentration: Potential Relevance to COVID-19 Risk. *Circulation*, **2020**, 142, 1117-1119 | 16.7 | 11 |
| 136 | Non-O blood group is associated with lower risk of in-hospital mortality in non-surgically managed patients with type A aortic dissection. *BMC Cardiovascular Disorders*, **2020**, 20, 515 | 2.3 | |
| 135 | The role of the LncRNA-FA2H-2-MLKL pathway in atherosclerosis by regulation of autophagy flux and inflammation through mTOR-dependent signaling. *Cell Death and Differentiation*, **2019**, 26, 1670-1687 | 12.7 | 76 |
| 134 | HHIPL1, a Gene at the 14q32 Coronary Artery Disease Locus, Positively Regulates Hedgehog Signaling and Promotes Atherosclerosis. *Circulation*, **2019**, 140, 500-513 | 16.7 | 15 |
| 133 | Microarray profiling analysis and validation of novel long noncoding RNAs and mRNAs as potential biomarkers and their functions in atherosclerosis. *Physiological Genomics*, **2019**, 51, 644-656 | 3.6 | 16 |
| 132 | Long noncoding RNA NEXN-AS1 mitigates atherosclerosis by regulating the actin-binding protein NEXN. *Journal of Clinical Investigation*, **2019**, 129, 1115-1128 | 15.9 | 61 |
| 131 | Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002196 | 5.2 | 9 |
| 130 | Genetic and Pharmacologic Inhibition of the Neutrophil Elastase Inhibits Experimental Atherosclerosis. *Journal of the American Heart Association*, **2018**, 7, | 6 | 23 |
| 129 | The biological impact of blood pressure-associated genetic variants in the natriuretic peptide receptor C gene on human vascular smooth muscle. *Human Molecular Genetics*, **2018**, 27, 199-210 | 5.6 | 11 |
| 128 | Influence of a Coronary Artery Disease-Associated Genetic Variant on FURIN Expression and Effect of Furin on Macrophage Behavior. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 1837-1844 | 9.4 | 13 |
| 127 | Subcutaneous Injection of Nitroglycerin at the Radial Artery Puncture Site Reduces the Risk of Early Radial Artery Occlusion After Transradial Coronary Catheterization: A Randomized, Placebo-Controlled Clinical Trial. *Circulation: Cardiovascular Interventions*, **2018**, 11, e006571 | 6 | 24 |
| 126 | Propofol Suppresses Proinflammatory Cytokine Production by Increasing ABCA1 Expression via Mediation by the Long Noncoding RNA LOC286367. *Mediators of Inflammation*, **2018**, 2018, 8907143 | 4.3 | 8 |

| | | | |
|---|---|---|---|
| 125 | Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention. *Journal of the American College of Cardiology*, **2018**, 72, 1883-1893 | 15.1 | 285 |
| 124 | JCAD, a Gene at the 10p11 Coronary Artery Disease Locus, Regulates Hippo Signaling in Endothelial Cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 1711-1722 | 9.4 | 19 |
| 123 | Increased NBCn1 expression, Na+/HCO3- co-transport and intracellular pH in human vascular smooth muscle cells with a risk allele for hypertension. *Human Molecular Genetics*, **2017**, 26, 989-1002 | 5.6 | 18 |
| 122 | Genetic Variation at the Locus is Associated With Reduced Severity of Coronary Artery Disease. *Journal of the American Heart Association*, **2017**, 6, | 6 | 17 |
| 121 | LBOS 02-04 BLOOD PRESSURE-ASSOCIATED POLYMORPHISMS IN SLC4A7 (SODIUM/BICARBONATE CO-TRANSPORTER NBCn1) ARE LINKED TO GENE EXPRESSION AND INTRACELLULAR pH REGULATION. *Journal of Hypertension*, **2016**, 34, e549-e550 | 1.9 | 1 |
| 120 | Association of MicroRNAs and YRNAs With Platelet Function. *Circulation Research*, **2016**, 118, 420-432 | 15.7 | 125 |
| 119 | Coronary-Heart-Disease-Associated Genetic Variant at the COL4A1/COL4A2 Locus Affects COL4A1/COL4A2 Expression, Vascular Cell Survival, Atherosclerotic Plaque Stability and Risk of Myocardial Infarction. *PLoS Genetics*, **2016**, 12, e1006127 | 6 | 31 |
| 118 | Difference in Leukocyte Composition between Women before and after Menopausal Age, and Distinct Sexual Dimorphism. *PLoS ONE*, **2016**, 11, e0162953 | 3.7 | 42 |
| 117 | A blood pressure-associated variant of the SLC39A8 gene influences cellular cadmium accumulation and toxicity. *Human Molecular Genetics*, **2016**, 25, 4117-4126 | 5.6 | 37 |
| 116 | MicroRNA-22 regulates smooth muscle cell differentiation from stem cells by targeting methyl CpG-binding protein 2. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 918-29 | 9.4 | 48 |
| 115 | A Novel Role of Matrix Metalloproteinase-8 in Macrophage Differentiation and Polarization. *Journal of Biological Chemistry*, **2015**, 290, 19158-72 | 5.4 | 25 |
| 114 | Effect of genetic polymorphisms involved in folate metabolism on the concentration of serum folate and plasma total homocysteine (p-tHcy) in healthy subjects after short-term folic acid supplementation: a randomized, double blind, crossover study. *Genes and Nutrition*, **2015**, 10, 456 | 4.3 | 17 |
| 113 | Effects of polymorphisms in endothelial nitric oxide synthase and folate metabolizing genes on the concentration of serum nitrate, folate, and plasma total homocysteine after folic acid supplementation: a double-blind crossover study. *Nutrition*, **2015**, 31, 337-44 | 4.8 | 4 |
| 112 | 189 Genetic Variation in ADAMTS7 is Associated with Severity of Coronary Artery Disease. *Heart*, **2015**, 101, A105.3-A106 | 5.1 | |
| 111 | Upregulated sirtuin 1 by miRNA-34a is required for smooth muscle cell differentiation from pluripotent stem cells. *Cell Death and Differentiation*, **2015**, 22, 1170-80 | 12.7 | 47 |
| 110 | Putative targeting of matrix metalloproteinase-8 in atherosclerosis. *Pharmacology & Therapeutics*, **2015**, 147, 111-22 | 13.9 | 15 |
| 109 | A simple high-performance liquid chromatography (HPLC) method for the measurement of pyridoxal-5-phosphate and 4-pyridoxic acid in human plasma. *Clinica Chimica Acta*, **2014**, 433, 150-6 | 6.2 | 13 |
| 108 | Analysis of circulating cholesterol levels as a mediator of an association between ABO blood group and coronary heart disease. *Circulation: Cardiovascular Genetics*, **2014**, 7, 43-8 | | 45 |

| | | | |
|---|---|---|---|
| 107 | 203 Hypoxia-inducible Factor-1 Regulates Matrix Metalloproteinase-14 Expression: Underlying Effects of Hypoxia and Statins. *Heart*, **2014**, 100, A111.2-A112 | 5.1 | 2 |
| 106 | Matrix metalloproteinase-8 promotes vascular smooth muscle cell proliferation and neointima formation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2014**, 34, 90-8 | 9.4 | 44 |
| 105 | ADAMTS7 cleavage and vascular smooth muscle cell migration is affected by a coronary-artery-disease-associated variant. *American Journal of Human Genetics*, **2013**, 92, 366-74 | 11 | 75 |
| 104 | Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. *Journal of the American College of Cardiology*, **2013**, 61, 957-70 | 15.1 | 56 |
| 103 | MicroRNA-200C and -150 play an important role in endothelial cell differentiation and vasculogenesis by targeting transcription repressor ZEB1. *Stem Cells*, **2013**, 31, 1749-62 | 5.8 | 48 |
| 102 | Functional involvements of heterogeneous nuclear ribonucleoprotein A1 in smooth muscle differentiation from stem cells in vitro and in vivo. *Stem Cells*, **2013**, 31, 906-17 | 5.8 | 26 |
| 101 | An important role of matrix metalloproteinase-8 in angiogenesis in vitro and in vivo. *Cardiovascular Research*, **2013**, 99, 146-55 | 9.9 | 65 |
| 100 | Functional role of matrix metalloproteinase-8 in stem/progenitor cell migration and their recruitment into atherosclerotic lesions. *Circulation Research*, **2013**, 112, 35-47 | 15.7 | 44 |
| 99 | Influence of matrix metalloproteinase-12 on fibrinogen level. *Atherosclerosis*, **2012**, 220, 351-4 | 3.1 | 7 |
| 98 | Comment on: "A promoter polymorphism (rs17222919, -1316T/G) of ALOX5AP is associated with intracerebral hemorrhage in Korean population" by Hwan Kim D. et al. [Prostaglandins Leukot. Essent. Fatty Acids 85 (2011) 115-120]. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **2012**, 86, 135-6 | 2.8 | 1 |
| 97 | Chromosome 1p13 genetic variants antagonize the risk of myocardial infarction associated with high ApoB serum levels. *BMC Cardiovascular Disorders*, **2012**, 12, 90 | 2.3 | 7 |
| 96 | Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells. *Human Molecular Genetics*, **2012**, 21, 4021-9 | 5.6 | 118 |
| 95 | Nrf3-Pla2g7 interaction plays an essential role in smooth muscle differentiation from stem cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 730-44 | 9.4 | 44 |
| 94 | Functional impact of heterogeneous nuclear ribonucleoprotein A2/B1 in smooth muscle differentiation from stem cells and embryonic arteriogenesis. *Journal of Biological Chemistry*, **2012**, 287, 2896-906 | 5.4 | 27 |
| 93 | Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. *European Heart Journal*, **2012**, 33, 393-407 | 9.5 | 75 |
| 92 | Common variant on chromosome 9p21 predicts severity of coronary artery disease. *Journal of the American College of Cardiology*, **2011**, 57, 1497-8; author reply 1498-9 | 15.1 | 8 |
| 91 | Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. *Diabetes*, **2011**, 60, 2624-34 | 0.9 | 285 |
| 90 | Toll-like receptors, their ligands, and atherosclerosis. *Scientific World Journal, The*, **2011**, 11, 437-53 | 2.2 | 24 |

| | | | |
|---|---|---|---|
| 89 | Association of MMP8 gene variation with an increased risk of malignant melanoma. *Melanoma Research*, **2011**, 21, 464-8 | 3.3 | 18 |
| 88 | Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nature Genetics*, **2011**, 43, 333-8 | 36.3 | 1394 |
| 87 | Large-scale gene-centric analysis identifies novel variants for coronary artery disease. *PLoS Genetics* , **2011**, 7, e1002260 | 6 | 175 |
| 86 | Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. *American Journal of Human Genetics*, **2011**, 89, 619-27 | 11 | 145 |
| 85 | Association of variation at the ABO locus with circulating levels of soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin: a meta-analysis. *Circulation: Cardiovascular Genetics*, **2011**, 4, 681-6 | | 59 |
| 84 | Genetic determinants of coronary heart disease: new discoveries and insights from genome-wide association studies. *Heart*, **2011**, 97, 1463-73 | 5.1 | 17 |
| 83 | The genetics of epigenetics: is there a link with cardiovascular disease. *Heart*, **2011**, 97, 96-7 | 5.1 | 4 |
| 82 | Chromobox protein homolog 3 is essential for stem cell differentiation to smooth muscles in vitro and in embryonic arteriogenesis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 1842-52 | 9.4 | 23 |
| 81 | PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. *Circulation*, **2010**, 121, 2284-93 | 16.7 | 90 |
| 80 | Coronary artery disease-related genetic variant on chromosome 10q11 is associated with carotid intima-media thickness and atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 2678-83 | 9.4 | 28 |
| 79 | Sp1-dependent activation of HDAC7 is required for platelet-derived growth factor-BB-induced smooth muscle cell differentiation from stem cells. *Journal of Biological Chemistry*, **2010**, 285, 38463-72 | 5.4 | 31 |
| 78 | Single nucleotide polymorphism on chromosome 9p21 and endothelial progenitor cells in a general population cohort. *Atherosclerosis*, **2010**, 208, 451-5 | 3.1 | 6 |
| 77 | ADAM33 expression in atherosclerotic lesions and relationship of ADAM33 gene variation with atherosclerosis. *Atherosclerosis*, **2010**, 211, 224-30 | 3.1 | 23 |
| 76 | Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. *Atherosclerosis*, **2010**, 212, 252-9 | 3.1 | 179 |
| 75 | Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. *Lancet, The*, **2010**, 375, 1634-9 | 40 | 520 |
| 74 | Genetic polymorphisms in the endotoxin receptor may influence platelet count as part of the acute phase response in critically ill children. *Intensive Care Medicine*, **2010**, 36, 1023-32 | 14.5 | 2 |
| 73 | Allele-specific regulation of matrix metalloproteinase-3 gene by transcription factor NFkappaB. *PLoS ONE*, **2010**, 5, e9902 | 3.7 | 30 |
| 72 | Different effects of angiotensin II and angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration. *PLoS ONE*, **2010**, 5, e12323 | 3.7 | 63 |

| | | | |
|---|---|---|---|
| 71 | Single nucleotide polymorphism genotyping in MMP genes: the 5Pnuclease assay. *Methods in Molecular Biology*, **2010**, 622, 221-9 | 1.4 | |
| 70 | Myopia and polymorphisms in genes for matrix metalloproteinases **2009**, 50, 2632-6 | | 40 |
| 69 | A role of matrix metalloproteinase-8 in atherosclerosis. *Circulation Research*, **2009**, 105, 921-9 | 15.7 | 99 |
| 68 | Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. *BMC Cancer*, **2008**, 8, 77 | 4.8 | 50 |
| 67 | Functional Toll-like receptor 4 mutations modulate the response to fibrinogen. *Thrombosis and Haemostasis*, **2008**, 100, 301-307 | 7 | 48 |
| 66 | Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis: a population-based, prospective study. *Journal of the American College of Cardiology*, **2008**, 52, 378-84 | 15.1 | 130 |
| 65 | Plasma MMP1, MMP8 and MMP13 expression in breast cancer: protective role of MMP8 against lymph node metastasis. *Breast Cancer Research*, **2008**, 10, | 8.3 | 2 |
| 64 | Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 2275-81 | 9.4 | 112 |
| 63 | Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression. *Pharmacogenetics and Genomics*, **2008**, 18, 803-13 | 1.9 | 33 |
| 62 | Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. *Clinical Genetics*, **2008**, 73, 197-211 | 4 | 43 |
| 61 | SDF1 gene variation is associated with circulating SDF1alpha level and endothelial progenitor cell number: the Bruneck Study. *PLoS ONE*, **2008**, 3, e4061 | 3.7 | 49 |
| 60 | Variation in the matrix metalloproteinase-3, -7, -12 and -13 genes is associated with functional status in rheumatoid arthritis. *International Journal of Immunogenetics*, **2007**, 34, 81-5 | 2.3 | 37 |
| 59 | Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. *Cancer Research*, **2007**, 67, 10214-21 | 10.1 | 70 |
| 58 | Functional polymorphism in ABCA1 influences age of symptom onset in coronary artery disease patients. *Human Molecular Genetics*, **2007**, 16, 1412-22 | 5.6 | 23 |
| 57 | Haplotype effects on matrix metalloproteinase-1 gene promoter activity in cancer cells. *Molecular Cancer Research*, **2007**, 5, 221-7 | 6.6 | 11 |
| 56 | Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. *Cardiovascular Research*, **2006**, 69, 636-45 | 9.9 | 126 |
| 55 | Complement factor H Y402H gene polymorphism in coronary artery disease and atherosclerosis. *Atherosclerosis*, **2006**, 188, 213-4 | 3.1 | 14 |
| 54 | Duplications of proximal 16q flanked by heterochromatin are not euchromatic variants and show no evidence of heterochromatic position effect. *Cytogenetic and Genome Research*, **2006**, 114, 351-8 | 1.9 | 19 |

| | | | |
|---|---|---|---|
| 53 | CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents. *Pharmacogenetics and Genomics*, **2005**, 15, 839-50 | 1.9 | 47 |
| 52 | Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. *Pharmacogenetics and Genomics*, **2005**, 15, 15-21 | 1.9 | 67 |
| 51 | Association of the lymphotoxin-alpha gene Thr26Asn polymorphism with severity of coronary atherosclerosis. *Genes and Immunity*, **2005**, 6, 539-41 | 4.4 | 27 |
| 50 | Angiotensin II type I receptor gene polymorphism: anthropometric and metabolic syndrome traits. *Journal of Medical Genetics*, **2005**, 42, 396-401 | 5.8 | 23 |
| 49 | VEGF polymorphisms and severity of atherosclerosis. *Journal of Medical Genetics*, **2005**, 42, 485-90 | 5.8 | 85 |
| 48 | Mutation scanning by meltMADGE: validations using BRCA1 and LDLR, and demonstration of the potential to identify severe, moderate, silent, rare, and paucimorphic mutations in the general population. *Genome Research*, **2005**, 15, 967-77 | 9.7 | 18 |
| 47 | Genotypic effect of the -565C>T polymorphism in the ABCA1 gene promoter on ABCA1 expression and severity of atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 418-23 | 9.4 | 41 |
| 46 | Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. *Circulation Research*, **2005**, 97, 1070-6 | 15.7 | 71 |
| 45 | Late life metabolic syndrome, early growth, and common polymorphism in the growth hormone and placental lactogen gene cluster. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 5569-76 | 5.6 | 24 |
| 44 | Evidence of differing genotypic effects of PPARalpha in women and men. *Journal of Medical Genetics*, **2004**, 41, e79 | 5.8 | 7 |
| 43 | Transmission disequilibrium test of stromelysin-1 gene variation in relation to Crohnβ disease. *Journal of Medical Genetics*, **2004**, 41, e112 | 5.8 | 13 |
| 42 | Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2004**, 24, 551-7 | 9.4 | 73 |
| 41 | Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. *Stroke*, **2004**, 35, 1310-5 | 6.7 | 72 |
| 40 | Paucimorphic Alleles versus Polymorphic Alleles and Rare Mutations in Disease Causation: Theory, Observation and Detection. *Current Genomics*, **2004**, 5, 431-438 | 2.6 | 7 |
| 39 | Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. *Journal of Medical Genetics*, **2003**, 40, 773-80 | 5.8 | 158 |
| 38 | Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. *European Heart Journal*, **2003**, 24, 1668-71 | 9.5 | 57 |
| 37 | A study of mitochondrial DNA mutations in peripheral lymphocytes in an aging cohort. *Biochemical Society Transactions*, **2003**, 31, 444-6 | 5.1 | 4 |
| 36 | Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. *Journal of Molecular Medicine*, **2003**, 81, 321-6 | 5.5 | 83 |

| | | | |
|---|---|---|---|
| 35 | Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population. *Clinical and Experimental Allergy*, **2003**, 33, 1103-10 | 4.1 | 43 |
| 34 | Independent effects of the -219 G>T and epsilon 2/ epsilon 3/ epsilon 4 polymorphisms in the apolipoprotein E gene on coronary artery disease: the Southampton Atherosclerosis Study. *European Journal of Human Genetics*, **2003**, 11, 437-43 | 5.3 | 36 |
| 33 | Promoter polymorphism influences the effect of dexamethasone on transcriptional activation of the LTC4 synthase gene. *European Journal of Human Genetics*, **2003**, 11, 619-22 | 5.3 | 10 |
| 32 | TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. *Atherosclerosis*, **2003**, 170, 187-90 | 3.1 | 99 |
| 31 | Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. *Journal of the American College of Cardiology*, **2003**, 41, 2130-7 | 15.1 | 113 |
| 30 | Epistatic interaction between variations in the angiotensin I converting enzyme and angiotensin II type 1 receptor genes in relation to extent of coronary atherosclerosis. *British Heart Journal*, **2003**, 89, 1195-9 | | 24 |
| 29 | Microarray analysis of peroxisome proliferator-activated receptor-gamma induced changes in gene expression in macrophages. *Biochemical and Biophysical Research Communications*, **2003**, 308, 505-10 | 3.4 | 48 |
| 28 | Molecular pathogenesis of subarachnoid haemorrhage. *International Journal of Biochemistry and Cell Biology*, **2003**, 35, 1341-60 | 5.6 | 56 |
| 27 | Allelic association and functional studies of promoter polymorphism in the leukotriene C4 synthase gene (LTC4S) in asthma. *Thorax*, **2003**, 58, 417-24 | 7.3 | 61 |
| 26 | PCR designer for restriction analysis of various types of sequence mutation. *Bioinformatics*, **2002**, 18, 1688-9 | 7.2 | 7 |
| 25 | Insulin-like growth factor-I genotype and birthweight. *Lancet, The*, **2002**, 360, 945; author reply 945-6 | 40 | 13 |
| 24 | Epidemiology and the genetic basis of disease. *International Journal of Epidemiology*, **2001**, 30, 661-7 | 7.8 | 6 |
| 23 | PIRA PCR designer for restriction analysis of single nucleotide polymorphisms. *Bioinformatics*, **2001**, 17, 838-9 | 7.2 | 86 |
| 22 | Polymorphisms in matrix metalloproteinase-1, -3, -9, and -12 genes in relation to subarachnoid hemorrhage. *Stroke*, **2001**, 32, 2198-202 | 6.7 | 81 |
| 21 | Nicotine induced changes in gene expression by human coronary artery endothelial cells. *Atherosclerosis*, **2001**, 154, 277-83 | 3.1 | 128 |
| 20 | An efficient procedure for genotyping single nucleotide polymorphisms. *Nucleic Acids Research*, **2001**, 29, E88-8 | 20.1 | 684 |
| 19 | Microarray analysis of nicotine-induced changes in gene expression in endothelial cells. *Physiological Genomics*, **2001**, 5, 187-92 | 3.6 | 77 |
| 18 | Detecting polymorphisms in MMP genes. *Methods in Molecular Biology*, **2001**, 151, 367-75 | 1.4 | 4 |

| | | | |
|---|---|---|---|
| 17 | Genetic diversity in the matrix metalloproteinase family. Effects on function and disease progression. *Annals of the New York Academy of Sciences*, **2000**, 902, 27-37; discussion 37-8 | 6.5 | 25 |
| 16 | Tools for molecular genetic epidemiology: a comparison of MADGE methodology with other systems. *Biotechnology and Genetic Engineering Reviews*, **2000**, 17, 71-88 | 4.1 | |
| 15 | Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. *Circulation Research*, **2000**, 86, 998-1003 | 15.7 | 158 |
| 14 | Rapid genotype analysis of the matrix metalloproteinase-1 gene 1G/2G polymorphism that is associated with risk of cancer. *Matrix Biology*, **2000**, 19, 175-7 | 11.4 | 39 |
| 13 | Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. *Matrix Biology*, **2000**, 19, 623-9 | 11.4 | 288 |
| 12 | Rapid genotype analysis of the stromelysin gene 5A/6A polymorphism. *Atherosclerosis*, **2000**, 151, 587-9 | 3.1 | 35 |
| 11 | Detection of mutations and DNA polymorphisms in genes involved in cardiovascular diseases by polymerase chain reaction-single-strand conformation polymorphism analysis. *Methods in Molecular Medicine*, **1999**, 30, 3-12 | | |
| 10 | Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. *Circulation*, **1999**, 99, 1788-94 | 16.7 | 499 |
| 9 | Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. *Human Genetics*, **1999**, 105, 418-23 | 6.3 | 118 |
| 8 | Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. *American Journal of Cardiology*, **1999**, 83, 852-6 | 3 | 122 |
| 7 | Human stromelysin gene promoter activity is modulated by transcription factor ZBP-89. *FEBS Letters*, **1999**, 450, 268-72 | 3.8 | 42 |
| 6 | Matrix metalloproteinases: implication in vascular matrix remodelling during atherogenesis. *Clinical Science*, **1998**, 94, 103-10 | 6.5 | 50 |
| 5 | Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. *Journal of Biological Chemistry*, **1996**, 271, 13055-60 | 5.4 | 353 |
| 4 | European Atherosclerosis Research Study: genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction. *Arteriosclerosis,* | 9.4 | 94 |
| 3 | The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de Infarctus du Mycocarde. *Thrombosis and Haemostasis*, **1995**, 74, 837-41 | 7 | 33 |
| 2 | Polymorphism in the promoter region of the apolipoprotein AI gene associated with differences in apolipoprotein AI levels: the European Atherosclerosis Research Study. *Genetic Epidemiology*, **1994**, 11, 265-80 | 2.6 | 57 |
| 1 | Allele specific amplification by tetra-primer PCR. *Nucleic Acids Research*, **1992**, 20, 1152 | 20.1 | 76 |